Gedeon Richter announced the conclusion of an agreement with the company Mycenax Biotech on the purchase of the rights to the bioanalogue tocilizumab for the treatment of rheumatoid arthritis.
Under the agreement, Gedeon Richter receives worldwide rights to develop, manufacture and commercialize bioanalogue tocilizumab. The deal includes the transfer of cell lines, intellectual property rights, technological know-how and data about a drug you have already received Mycenax.
The parties agreed that payment would be done Gedeon Richter in four tranches and will amount to 16.5 million dollars. The company has already made a prepayment in the amount of 2 million dollars for exclusivity in the negotiation process, at the signing of the contract will be paid another $ 3 million as a down payment. It is expected that the bioanalogue tocilizumab will appear on the markets of the European Union, Canada, Australia and Japan in 2025.